German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015
We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies Advanced products / promising pipeline Highly attractive markets Highly qualified & dedicated team Close network with scientific institutions & experts
Strategic Focus: Outlicensing of Products to Generate High Returns License agreements with pharma companies High returns in the mid- and long-term Prioritize development of lead product MGN1703 High market potential Continue clinical development of MGN1601 Unique proprietary technology Develop vaccine candidates Support to treat diseases with high unmet medical need: Leishmaniasis & hepatitis B Initiate new projects Extend and advance product pipeline to ensure long-term growth 2015 3
Advanced Product Pipeline with Strong Focus on Cancer Immunotherapies Preclinical Phase I Phase II Phase III / Approval EnanDIM Oncology & Anti-infectives MGN1703 1 Other solid tumors MGN1703 1 Small cell lung cancer MGN1703 1 Colorectal cancer MGN1331 Leishmaniasis 3 MGN1333 Hepatitis B MGN1703 4 HIV MGN1601 Renal cancer MGN1404 2 Malignant melanoma Oncology Infectious diseases Oncology & Infectious diseases 1 IND (Investigational New Drug) filed in US; safety trial in US completed in 2014 2 Collaboration with Max-Delbrueck-Center for Molecular Medicine and Charité Universitaetsmedizin, Berlin 3 Various diseases caused by parasites; mainly present in subtropical and tropical regions (major neglected disease) 4 Collaboration with University Hospital Aarhus, Denmark 2015 4
Cancer Immunotherapies: New Megatrend Science Magazine: Breakthrough of the Year 2013 US$ 35,000,000,000 market potential* *Source: Citi-Bank 2013 estimated peak sales 2015 5
Immunotherapy: Superior Treatment Chemotherapy Fast effect in many patients Effect not lasting Patients alive in % Immunotherapy Needs time to be effective Long-lasting effect in a minority of patients Patients alive in % Chemotherapy Immunotherapy Control group time Control group time Source: "Immuno-oncology: The new weapon in the war against cancer, Alistair Campbell; Berenberg Equity Highlights, February 2014 2015 6
MGN1703: Best in Class TLR9 Agonist Activation profile and chemical structure supports application in cancer therapy High dosing over long periods of time without toxic effects Clinical strategy optimized for MGN1703 TLR9 activation pattern Maximized probability of success compared to other TLR9 agonists Light blue area: recognized by TLR9 receptor 2015 7
Activating the Immune System to Fight Cancer Cancer patient mdc myeloid dendritic cell NK cell natural killer cell NKT cell natural killer T cell pdc plasmacytoid dendritic cell 2015 8
MGN1703 Ongoing Clinical Trials IMPALA IMPULSE TEACH Metastatic Colorectal Cancer (mcrc) Pivotal trial (phase III) Smal Cell Lung Cancer (SCLC) Randomized study (phase II) HIV (Infectious Disease) Early Stage Study (phase I) 540 patients 8 European countries: Austria, Belgium, Estonia, France, Germany, Italy, Spain, UK Currently Recruiting 100 patients 4 European countries: Austria, Belgium, Germany, Spain Recruitment completed (Oct 2015) 16 patients Denmark Recruitment completed (Sep 2015) 2015 9
MGN1703 Milestones Clinical Trials IMPALA IMPULSE TEACH 2014 First patient in (FPI) First patient in (FPI) 2015 Recruitment completed Recruitment started and completed 2016 Recruitment completed Start of Primary analyses Start of Primary analyses Results 2017 Primary analyses First Results 2018 First Results 2019 2015 10
Conclusion: Late-Stage Product MGN1703 with Unique Profile and Huge Market Potential First-line maintenance Long-term treatment Usable for various indications (mcrc, SCLC, ) Superior safety and tolerability Blockbuster potential Suitable for mono- and combination therapy Patient selection via biomarker mcrc metastatic colorectal cancer SCLC small cell lung cancer 2015 11
Key Financials: 9M 2015 defined by study progress In million 9M 2015 9M 2014 R&D expenses 10.4 10.5-1% EBIT -13.3-13.3 0% R&D costs almost unchanged Monthly cash burn accordingly Capital increase reflected in financing cash flows Cash flows from operating activities Cash flows from financing activities -9.0-11.5-22% 26.1 14.7 81% Monthly cash burn 1.3 1.4 7% In million 30 Sep 2015 31 Dec 2014 Total assets 32.7 15.1 117% Main items impacted by capital increase of 28.3 m gross Cash & cash equivalents 30.5 13.6 124% Equity ratio 81% 88% -8% 2015 12
FY 2015: Outlook Confirmed Development of product pipeline well on track Intensify clinical development of MGN1703: Registration study IMPALA: Continue patient recruitment Randomized study IMPULSE: Finalize patient recruitment MGN1601: Plan and prepare continuative study in renal cancer Continue partnering discussions Increase of R&D expenses due to studies with MGN1703, mainly IMPALA 2015 13
Financial Calendar and Contact Details 22 March 2016 Annual Financial Statements and Annual Report 2015 12 May 2016 Quarterly Report as of 31 March 2016 11 August 2016 Half-Year Report as of 30 June 2016 10 November 2016 Quarterly Report as of 30 September 2016 Claudia Nickolaus Head of Investor Relations & Corporate Communications Phone: +49-30-841788-38 Fax: +49-30-841788-50 investor@mologen.com www.mologen.com 2015 MOLOGEN, MIDGE, dslim, and EnanDIM are registered trademarks of the 14
German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 2015 15